journal article·2011-09-15

Silk fibroin and polyethylene glycol‐based biocompatible tissue adhesives

Monica A. Serban, Bruce Panilaitis, David L. Kaplan

Publisher page

Abstract

Abstract Tissue sealants have emerged in recent years as strong candidates for hemostasis. A variety of formulations are currently commercially available and though they satisfy many of the markets' needs there are still key aspects of each that need improvement. Here we present a new class of blends, based on silk fibroin and chemically active polyethylene glycols (PEGs) with strong adhesive properties. These materials are cytocompatible, crosslink within seconds via chemical reaction between thiols and maleimides present on the constituent PEGs and have the potential to further stabilize through β‐sheet formation by silk. Based on the silk concentration in the final formulation, the adhesive properties of these materials are comparable or better than the current leading PEG‐based sealant. In addition, the silk‐PEG based materials show decreased swelling and longer degradation times. Such properties would make them suitable for applications for which the current sealants are contraindicated. © 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A:, 2011.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Silk-based biomaterials and applications · Surgical Sutures and Adhesives · Polymer Surface Interaction Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (27)

Show source-provided references
1. 10.1016/j.ucl.2009.02.00210.1016/j.ucl.2009.02.002 ↗
2. 10.1111/j.1537-2995.2008.01703.x10.1111/j.1537-2995.2008.01703.x ↗
3. Clinical and experimental observations on the use of gelatin sponge or foam
4. 10.1016/j.urology.2004.10.03010.1016/j.urology.2004.10.030 ↗
5. Evaluation of the topical hemostatic efficacy and safety of TISSEEL VH S/D fibrin sealant compared with currently licensed TISSEEL VH in patients undergoing cardiac surgery: A phase 3, randomized, double‐blind clinical study
6. 10.1016/S0090-4295(00)01075-X10.1016/S0090-4295(00)01075-X ↗
7. 10.1016/j.athoracsur.2004.11.05410.1016/j.athoracsur.2004.11.054 ↗
8. 10.3171/JNS-07/09/064210.3171/JNS-07/09/0642 ↗
9. 10.1046/j.0886-0440.2003.00305.x10.1046/j.0886-0440.2003.00305.x ↗
10. 10.1002/jbm.105310.1002/jbm.1053 ↗
11. 10.1007/s11095-008-9801-210.1007/s11095-008-9801-2 ↗
12. 10.1016/j.jmb.2003.10.04310.1016/j.jmb.2003.10.043 ↗
13. 10.1016/j.jconrel.2005.12.00910.1016/j.jconrel.2005.12.009 ↗
14. 10.1016/j.biomaterials.2008.11.01810.1016/j.biomaterials.2008.11.018 ↗
15. 10.1163/15685620878408960710.1163/156856208784089607 ↗
16. 10.1002/1097-4636(200101)54:1<139::AID-JBM17>3.0.CO;2-710.1002/1097-4636(200101)54:1<139::AID-JBM17>3.0.CO;2-7 ↗
17. 10.1002/prot.107810.1002/prot.1078 ↗
18. 10.1002/adma.20090264310.1002/adma.200902643 ↗
19. 10.1016/j.jsb.2009.12.01210.1016/j.jsb.2009.12.012 ↗
20. 10.1021/bm070356410.1021/bm0703564 ↗
21. 10.1021/bm025603c10.1021/bm025603c ↗
22. 10.1002/jbm.a.1012010.1002/jbm.a.10120 ↗
23. 10.1016/j.biomaterials.2004.09.02010.1016/j.biomaterials.2004.09.020 ↗
24. 10.1016/S0142-9612(02)00156-410.1016/S0142-9612(02)00156-4 ↗
25. 10.1021/bm034546010.1021/bm0345460 ↗
26. 10.1016/j.biomaterials.2006.01.02210.1016/j.biomaterials.2006.01.022 ↗
27. 10.1021/bm034327e10.1021/bm034327e ↗